Enoda
Transforming cells into cures.
United States · Founded 2023
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- enoda.bio
- Last Round
- SeedJan 2023
- Rounds
- 1
About
Enoda is a synthetic biology and cell therapy company developing a novel platform of synthetic cytokine receptors called MIMICs (Modular Immune-Mediated Intracellular Constructs) that engineer any cell type into a therapeutic cure. Co-founded in 2023 by Michael Chavez (CEO) and Paul Finn (CTO), the company's technology solves a core protein engineering challenge by linking Signal 3 cytokine signaling to clinically relevant inputs without systemic toxicity, expanding what engineered cells can do. Enoda's platform is designed for partnering with CAR T cell, regulatory T cell, macrophage, and stem cell therapy programs to expand the scope of durable cell therapy cures.
Summary
Enoda is a Biotech company based in United States, founded in 2023. Its most recent funding was a Seed round in Jan 2023. Investors include Fifty Years and Humba Ventures.
Funding History
2023 (est.)
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/enoda"><img src="https://indexed.vc/api/badge/company/enoda" alt="Enoda on Indexed.vc" width="260" height="76" /></a>